注意差距：一项调查研究显示，癌症药物载体如何容易受到研究与实践之间差距的影响。
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.
机构信息
University of Utah, Department of Bioengineering, College of Engineering, Salt Lake City, 84112, USA.
出版信息
J Control Release. 2013 Dec 28;172(3):1045-64. doi: 10.1016/j.jconrel.2013.09.026. Epub 2013 Oct 2.
Abstract
With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
摘要
有无数的研究论文使用临床前模型，展示了纳米颗粒设计优于目前用于治疗癌症的药物疗法的优势，但令人惊讶的是，这些纳米级药物载体在临床环境中的转化是多么不足。本文旨在比较 Doxil®、PK1、Abraxane®、Genexol-PM®、Xyotax™、NC-6004、Mylotarg®、PK2 和 CALAA-01 的临床前和临床结果。虽然不全面，但它涵盖了旨在提高化疗中常用药物疗效的纳米级药物载体。虽然并非总是可用或可比，但我们努力比较了动物和人体研究之间的药代动力学、毒性和疗效。讨论提供了导致差距的原因。最后，为纳米级药物载体的潜力提供了建议和鼓励。
相似文献
1
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.注意差距：一项调查研究显示，癌症药物载体如何容易受到研究与实践之间差距的影响。
J Control Release. 2013 Dec 28;172(3):1045-64. doi: 10.1016/j.jconrel.2013.09.026. Epub 2013 Oct 2.
2
Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?三氧化二砷纳米囊泡给药治疗实体瘤的研究进展
Mini Rev Med Chem. 2020;20(3):239-251. doi: 10.2174/1389557519666191018155426.
3
Graphene as multifunctional delivery platform in cancer therapy.石墨烯作为癌症治疗中的多功能递送平台。
J Biomed Mater Res A. 2017 Aug;105(8):2355-2367. doi: 10.1002/jbm.a.36080. Epub 2017 Jun 19.
4
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.近期紫杉醇类纳米给药系统治疗癌症的临床进展。
Int J Nanomedicine. 2020 Oct 22;15:8151-8166. doi: 10.2147/IJN.S272529. eCollection 2020.
5
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.癌症的先进靶向疗法：药物纳米载体，化疗的未来。
Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23.
6
A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.综述：整合素αvβ3靶向的血管生成分子成像与治疗
Nanomedicine. 2005 Jun;1(2):110-4. doi: 10.1016/j.nano.2005.03.008.
7
Cover Story: Nanoparticle properties affecting nuclear targeting in cancer and normal cells.封面故事：影响纳米颗粒在癌细胞和正常细胞中核靶向的性质
J Control Release. 2017 May 10;253:184. doi: 10.1016/j.jconrel.2017.04.008.
8
Graphene-based nanomaterials and their potentials in advanced drug delivery and cancer therapy.基于石墨烯的纳米材料及其在先进药物输送和癌症治疗中的潜力。
J Control Release. 2018 Sep 28;286:64-73. doi: 10.1016/j.jconrel.2018.07.034. Epub 2018 Jul 18.
9
Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.基于透明质酸的纳米载体靶向癌症：最新进展和转化视角。
Nanomedicine (Lond). 2016 Sep;11(17):2341-57. doi: 10.2217/nnm-2016-0117. Epub 2016 Aug 16.
10
Targeted nanosystems: Advances in targeted dendrimers for cancer therapy.靶向纳米系统：用于癌症治疗的靶向树枝状大分子的进展
Nanomedicine. 2016 Feb;12(2):309-16. doi: 10.1016/j.nano.2015.11.012. Epub 2015 Dec 17.
引用本文的文献
1
Targeted Cancer Therapy-on-A-Chip.靶向癌症治疗芯片
Adv Healthc Mater. 2024 Nov;13(29):e2400833. doi: 10.1002/adhm.202400833. Epub 2024 Aug 5.
2
Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer.聚合物偶联物作为联合治疗癌症的新型有前途的药物传递系统。
Curr Top Med Chem. 2024;24(13):1101-1119. doi: 10.2174/0115680266280603240321064308.
3
Supramolecular interaction in the action of drug delivery systems.药物递送系统作用中的超分子相互作用。
Chem Sci. 2024 Apr 30;15(21):7811-7823. doi: 10.1039/d3sc04585d. eCollection 2024 May 29.
4
Anti-lymphangiogenesis for boosting drug accumulation in tumors.抗淋巴管生成以促进药物在肿瘤中的蓄积。
Signal Transduct Target Ther. 2024 Apr 15;9(1):89. doi: 10.1038/s41392-024-01794-4.
5
Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.纳米治疗学的异质性：来源、影响与解决方案。
Small. 2024 Apr;20(17):e2307502. doi: 10.1002/smll.202307502. Epub 2023 Dec 5.
6
Stimuli-responsive crosslinked nanomedicine for cancer treatment.用于癌症治疗的刺激响应性交联纳米药物
Exploration (Beijing). 2022 Apr 21;2(6):20210134. doi: 10.1002/EXP.20210134. eCollection 2022 Dec.
7
Establishing a simple perfusion cell culture system for light-activated liposomes.建立简单的灌注细胞培养系统用于光激活脂质体。
Sci Rep. 2023 Feb 4;13(1):2050. doi: 10.1038/s41598-023-29215-6.
8
[Research progress on the fluorescence resonance energy transfer-based polymer micelles as drug carriers].基于荧光共振能量转移的聚合物胶束作为药物载体的研究进展
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2022 Oct 25;39(5):1022-1032. doi: 10.7507/1001-5515.202111040.
9
Hydroxyethyl starch based smart nanomedicine.基于羟乙基淀粉的智能纳米药物
RSC Adv. 2021 Jan 14;11(6):3226-3240. doi: 10.1039/d0ra09663f.
10
An Overview of Nanotechnologies for Drug Delivery to the Brain.用于脑部药物递送的纳米技术概述。
Pharmaceutics. 2022 Jan 19;14(2):224. doi: 10.3390/pharmaceutics14020224.
本文引用的文献
1
Structural studies of several clinically important oncology drugs in complex with human serum albumin.几种临床上重要的肿瘤药物与人类血清白蛋白复合物的结构研究。
Biochim Biophys Acta. 2013 Dec;1830(12):5356-74. doi: 10.1016/j.bbagen.2013.06.032. Epub 2013 Jul 6.
2
Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial.紫杉醇载药聚合物胶束（230mg/m²）联合顺铂（60mg/m²）对比紫杉醇（175mg/m²）联合顺铂（60mg/m²）治疗晚期非小细胞肺癌的多中心随机 IIB 期临床试验。
Clin Lung Cancer. 2013 May;14(3):275-82. doi: 10.1016/j.cllc.2012.11.005. Epub 2013 Jan 3.
3
Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma.基于纳米聚合物的药物 NC-6004 靶向肿瘤化疗治疗口腔鳞状细胞癌。
Cancer Sci. 2013 Mar;104(3):369-74. doi: 10.1111/cas.12079. Epub 2013 Jan 30.
4
Review: ototoxic characteristics of platinum antitumor drugs.综述：铂类抗肿瘤药物的耳毒性特征。
Anat Rec (Hoboken). 2012 Nov;295(11):1851-67. doi: 10.1002/ar.22577. Epub 2012 Oct 8.
5
Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.含环糊精聚合物：药物递送材料的多功能平台
J Drug Deliv. 2012;2012:262731. doi: 10.1155/2012/262731. Epub 2012 Feb 2.
6
Doxil®--the first FDA-approved nano-drug: lessons learned.多西紫杉醇脂质体（Doxil®）——首个获美国 FDA 批准的纳米药物：经验教训。
J Control Release. 2012 Jun 10;160(2):117-34. doi: 10.1016/j.jconrel.2012.03.020. Epub 2012 Mar 29.
7
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.吉西他滨联合白蛋白紫杉醇在晚期胰腺癌患者中具有活性：一项 I/II 期试验。
J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.
8
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.肿瘤靶向药物递送：原理、陷阱和（临床前）进展。
J Control Release. 2012 Jul 20;161(2):175-87. doi: 10.1016/j.jconrel.2011.09.063. Epub 2011 Sep 16.
9
Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.聚乙二醇脂质体阿霉素的药理学基础：对癌症治疗的影响。
Eur J Pharm Sci. 2012 Mar 12;45(4):388-98. doi: 10.1016/j.ejps.2011.09.006. Epub 2011 Sep 10.
10
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.阿糖胞苷联合柔红霉素与阿糖胞苷联合吉妥珠单抗奥唑米星治疗 AML 的诱导治疗：老年患者的一项随机 II 期试验。
Ann Oncol. 2012 Apr;23(4):990-6. doi: 10.1093/annonc/mdr346. Epub 2011 Aug 2.
Zotero 插件